Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 11/20 | 0.45 |
| ▸ | PGR | P06401 | 6/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705085 | 0.83 | NR3C2 (0.50) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL8202873 | 0.80 | NR3C2 (0.45) | NR3C2PGRNR3C1PARP1MMP12 | |
| SCHEMBL12116980 | 0.80 | PDE3B (0.53) | NR3C2PGRNR3C1PARP1MMP12 | |
| SCHEMBL21372202 | 0.80 | NR3C2 (0.48) | NR3C2PGRNR3C1PARP1MMP12 | |
| SCHEMBL29939223 | 0.80 | NR3C2 (0.45) | NR3C2PGRNR3C1PARP1MMP12 | |
| SCHEMBL21552373 | 0.80 | PGR (0.45) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL4102483 | 0.80 | NR3C2 (0.45) | NR3C2PGRNR3C1PARP1MMP12 | |
| SCHEMBL3276712 | 0.78 | NR3C2 (0.44) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL29952529 | 0.78 | NR3C2 (0.44) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL5258793 | 0.76 | NR3C2 (0.43) | NR3C2PGRNR3C1MMP12PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | Bugworks Research, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2017199265-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711011-B2 | Substituted oxazolidines as anti-bacterial agents | ALPI, HLA-A, HLA-B | NR3C2 2377/4885PGR 4796/4885NR3C1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.